Article
Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Journal of clinical pharmacy and therapeutics - 1 Oct 2016
Adeagbo B A, Bolaji O O, Olugbade T A, Durosinmi M A, Bolarinwa R A, Masimirembwa C
Abstract excerpt
WHAT IS KNOWN AND OBJECTIVE: Imatinib mesylate is the first-line drug for the treatment of Philadelphia/bcr-abl positive chronic myeloid leukaemia (CML). It is known to be metabolized mostly by CYP3A4 and CYP3A5 isoforms while its efflux is mediated by the transporters ABCB1 and ABCG2. Genetic polymorphism of some of these enzymes and transporters have been linked with inter-individual variations in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
